Holocene Advisors, LP Xenon Pharmaceuticals Inc. Transaction History

Holocene Advisors, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $18.2 Million - $21.2 Million	-534,008 Reduced 74.95%	178,470 $6.1 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $9.54 Million - $11.9 Million	-273,717 Reduced 27.75%	712,478 $27.4 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $6.87 Million - $8.29 Million	-205,443 Reduced 17.24%	986,195 $35.3 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $21.1 Million - $25.1 Million	-637,514 Reduced 34.85%	1,191,638 $47 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $23.4 Million - $32.3 Million	919,524 Added 101.09%	1,829,152 $55.6 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $22.8 Million - $30.1 Million	909,628 New	909,628 $27.8 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.